ロード中...
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions play a critical role in the evasion of apoptosis and are theref...
保存先:
| 出版年: | Cancer Med |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6434202/ https://ncbi.nlm.nih.gov/pubmed/30701699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1995 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|